Stock MarketROI
Closed
PFE

PFEPfizer Inc.

NYSE

Healthcare · Drug Manufacturers - General

$24.72-1.44%
Mkt Cap: $140.89BDY: 6.96%

Pfizer Inc. (PFE) stock trades at $24.72, down 1.44% on the day. With a market capitalization of $140.89 billion, PFE is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 18.9, a forward P/E of 8.7 and earnings per share (EPS) of $1.31. Over the most recent period the company reported 5% year-over-year revenue growth and a net profit margin of 11.8%. Below you'll find PFE's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.

Price & Performance

Performance

Analysis & Verdict

Pfizer Inc. (PFE) Stock Analysis 2026

Rule-based · Updated daily · Not financial advice

Pfizer Inc. (PFE) operates in the Drug Manufacturers - General space within the Healthcare sector. With a market cap of $140.9B, it qualifies as a mid-cap company. Growth is moderate and the business remains profitable, offering a balanced risk/reward profile compared to high-multiple peers.

Bull Case5
  • Forward P/E (8.7×) is lower than trailing P/E (18.9×) — analysts expect earnings to improve
  • Revenue growth of 5% YoY shows solid business momentum
  • Healthy profit margin of 11.8%
  • Dividend yield of 6.96% provides consistent income on top of price appreciation
  • Low beta of 0.29 — less volatile than the market, suitable for conservative portfolios
Bear Case2
  • Earnings fell 10% YoY — profitability is under pressure
  • High debt-to-equity of 71.60× increases financial risk, especially with elevated interest rates

Verdict

Strong Buy

Multiple fundamental strengths with few red flags. Long-term buyers may find this compelling.

AI Insight

Powered by Claude

AI-generated analysis for informational purposes only. Not financial advice.

Fair Value Estimates

Current price: $24.72

Graham Number

√(22.5 × EPS × Book Value)

$21.59

-12.7% downside

Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.

Bazin Ceiling Price

Avg. Annual DPS (5Y) ÷ 6%

$27.33

+10.6% upside

Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.

These are simplified estimates. Not financial advice.

Buy & Hold Checklist

Quality criteria for long-term holding

7/10

70% score

Pays dividends

15Y hist.

15+ years of dividend history

Dividend consistency (5Y+)

15 yrs

Uninterrupted dividend payments for at least 5 years

ROE above 10%

8.3%

Return on equity — measures how efficiently capital is used

Positive profit margin

11.8%

Net profit margin must be positive — company earns more than it spends

Revenue growth (annual)

+5.4%

Annual revenue must be growing compared to the prior year

Earnings growth (annual)

-10.1%

Annual earnings must be growing compared to the prior year

Debt/Equity below 2×

71.60×

Low financial leverage reduces risk of distress

Current ratio above 1

1.25×

Short-term assets must cover short-term liabilities

Daily liquidity above $5M

$905M/day

High trading volume ensures easy entry and exit

Dividend yield above 0%

6.96%

Stock must distribute income to shareholders

Financials

Revenue & Results

Key Statistics

Market Cap$140.89B
P/E Ratio18.87
Forward P/E8.74
P/B Ratio
PEG Ratio13.77

Earnings

Next Earnings

Aug 4, 2026

41

days

EPS (TTM)

$1.31

P/E (TTM)

18.9

Fwd P/E

8.7

SEC Filings & Reported Financials

Earnings History

SEC EDGAR · official filings

SEC filings

SEC Filings

Official EDGAR documents

All filings

Insider Transactions

SEC Form 4 · officers, directors & 10% owners

Dividends & Income

Dividends

Current DY

6.96%

5Y Avg Annual

$1.5000

Last Payment

$0.4300

Ex-Date

05/08/2026

Annual dividends paid per share

2011
2019
2026
Ex-DatePaymentAmountEst. DY
Latest05/08/2026
06/12/2026$0.43006.96%
01/23/2026
02/27/2026$0.43006.96%
11/07/2025
12/12/2025$0.43006.96%
07/25/2025
08/29/2025$0.43006.96%
05/09/2025
06/13/2025$0.43006.96%
01/24/2025
02/28/2025$0.43006.96%
11/08/2024
12/13/2024$0.42006.80%
07/26/2024
08/30/2024$0.42006.80%

Magic Number

Shares needed to self-fund your next purchase

$24.72

Price

÷

$0.4300

Last div. (quarterly)

=

58

shares

Own 58 PFE shares ($1,433.76) and each quarterly dividend pays for 1 new share — the snowball runs on its own.

Investment target

$1,433.76

New shares / year

+4 shares

Tools & Simulators

If You Had Invested…

Hypothetical return based on historical prices

$

* Dividend reinvestment calculated at ex-date price. For informational purposes only.

Discover

Related Assets

Healthcare

Related Articles

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector

Healthcare

Industry

Drug Manufacturers - General

Location

New York, United States

Employees

75,000

Listed on NYSE

PFE — Frequently Asked Questions

Is Pfizer Inc. (PFE) a good stock to buy in 2026?

Pfizer Inc. (PFE) shows risks such as high leverage (debt/equity of 71.6). Whether PFE is a good buy in 2026 depends on your time horizon and risk tolerance — review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.

What is PFE's stock price today?

Pfizer Inc. (PFE) trades at $24.72, down 1.44% on the session. Prices on this page update throughout the trading day.

Does PFE pay a dividend?

Yes. Pfizer Inc. pays an annual dividend of $1.72 per share, a dividend yield of 6.96%. The most recent ex-dividend date was May 8, 2026. Its payout ratio is about 131% of earnings.

Is PFE overvalued?

With a P/E ratio of 18.9×, PFE trades at a roughly market-average valuation for the healthcare sector. Its PEG ratio is 13.77. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.

What is PFE's market cap?

Pfizer Inc. (PFE) has a market capitalization of $140.89 billion, classifying it as a large-cap stock in the Healthcare sector.

Disclaimer: This page — including any buy/hold/avoid view, fair value or price estimate — is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.